½ÃÀ庸°í¼­
»óǰÄÚµå
1590818

À¯ÀüÀÚ ÆíÁý ½ÃÀå : ±â¼ú, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Genome Editing Market by Technology (Antisense, CRISPR, Talen), Application (Cell Line Engineering, Genetic Engineering), End User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 192 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

À¯ÀüÀÚ ÆíÁý ½ÃÀåÀº 2023³â¿¡ 108¾ï ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 165¾ï 4,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 53.22%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 2,142¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

»ý¹°Ã¼ÀÇ DNA¸¦ º¯Çü½ÃŰ´Â °úÇÐÀû Á¢±Ù ¹æ½ÄÀÎ À¯ÀüÀÚ ÆíÁýÀº ³ó¾÷¿¡¼­ ÇコÄɾ À̸£±â±îÁö ´Ù¾çÇÑ ºÐ¾ß¿¡¼­ Å« ÁöÁö¸¦ ¹Þ°í ÀÖ½À´Ï´Ù. ÀÌ ±â¼úÀº ¿øÇϴ ƯÁ¤ ÇüÁúÀ» °¡Áø À¯ÀüÀÚ º¯Çü »ý¹°À» ¸¸µé¾î³»´Â ´É·Â¿¡ ÀÖ¾î ¸Å¿ì Áß¿äÇϸç, ÀÛ¹°ÀÇ Áúº´ ÀúÇ×¼º ¹× ÀÇ·á ºÐ¾ßÀÇ Ä¡·á¹ý °³¹ßÀÇ ¹ßÀü°ú °°Àº ¹®Á¦¸¦ ÇØ°áÇϰí ÀÖ½À´Ï´Ù. À¯Àüü ÆíÁýÀÇ Çʿ伺Àº Á¤È®ÇÏ°í ºñ¿ë È¿À²ÀûÀÎ À¯ÀüÀÚ Á¶ÀÛÀ» ÅëÇØ ½Ä·® ¾Èº¸¿Í À¯ÀüÀû Áúº´°ú °°Àº ½Ã±ÞÇÑ ¼¼°è ¹®Á¦¸¦ ÇØ°áÇÒ ¼ö ÀÖ´Â ÀáÀç·Â¿¡¼­ ºñ·ÔµË´Ï´Ù. ÁÖ¿ä ¿ëµµ´Â ÇØÃæ¿¡ °­ÇÏ°í ¼öÈ®·®ÀÌ ¸¹Àº ÀÛ¹°À» °³¹ßÇϱâ À§ÇÑ ³ó¾÷ ºÐ¾ß¿Í À¯ÀüÀÚ ÁúȯÀ» Ä¡·áÇϱâ À§ÇÑ À¯ÀüÀÚ Ä¡·á¸¦ Áß½ÉÀ¸·Î ÇÑ ÇコÄÉ¾î ºÐ¾ßÀÔ´Ï´Ù. ¶ÇÇÑ, ¹ÙÀÌ¿À¿¬·á »ý»ê°ú ȯ°æ ±â¼úÀ» À§ÇÑ »ê¾÷ »ý¸í°øÇÐ ºÐ¾ß¿¡¼­µµ ºñ¾àÀûÀÎ ¹ßÀüÀÌ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023³â) 108¾ï ´Þ·¯
¿¹Ãø ¿¬µµ(2024³â) 165¾ï 4,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 2,142¾ï 2,000¸¸ ´Þ·¯
CAGR(%) 53.22%

À¯ÀüÀÚ ÆíÁý ½ÃÀåÀÇ ¼ºÀåÀº ÁÖ·Î °í±Þ Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, »ý¸í°øÇÐ ±â¼úÀÇ Áö¼ÓÀûÀÎ ¹ßÀü, À¯Àü Áúȯ¿¡ ´ëÇÑ ÀÌÇØ Áõ°¡·Î ÀÎÇØ ¹ß»ýÇÕ´Ï´Ù. ÃֽŠºñÁî´Ï½º ±âȸ·Î´Â Ä¡·áÁ¦ÀÇ CRISPR Àû¿ë È®´ë¿Í Áö¼Ó °¡´ÉÇϰí ź·ÂÀûÀÎ ½Ä·® ½Ã½ºÅÛÀ» Áö¿øÇϱâ À§ÇÑ ÀÛ¹° °³·® ÇÁ·Î±×·¥À» µé ¼ö ÀÖ½À´Ï´Ù. ¿¬±¸±â°ü¿¡ ÅõÀÚÇϰųª ÆÄÆ®³Ê½ÊÀ» ¸Î´Â ±â¾÷µéÀº À¯Àüü ÆíÁýÀÇ Æ¯Çã °¡´ÉÇÑ ½Å±â¼úÀ» Ȱ¿ëÇÏ°í ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀ» ¹Þ¾Æ ½ÅÈï ½ÃÀå¿¡ ºü¸£°Ô ÁøÀÔÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷¿¡ ´ëÇÑ ÁÖ¿ä ±Ç°í»çÇ×Àº º¸´Ù Á¤È®Çϰí Ç¥Àû¿¡¼­ ¹þ¾î³­ È¿°ú°¡ ÀûÀº À¯ÀüÀÚ ÆíÁý µµ±¸ÀÇ °³¹ß°ú R&D ¿ª·®À» °­È­Çϱâ À§ÇÑ ÆÄÆ®³Ê½Ê È®´ë¿¡ ÃÊÁ¡À» ¸ÂÃâ °ÍÀ» ±Ç°íÇÕ´Ï´Ù.

±×·¯³ª À¯ÀüÀÚ º¯Çü¿¡ ´ëÇÑ À±¸®Àû ¿ì·Á, ¾ö°ÝÇÑ ±ÔÁ¦ ȯ°æ, ½ÃÀå µµÀÔ¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ´Â ÀáÀçÀû »çȸ°æÁ¦Àû °ÝÂ÷ µî ½ÃÀåÀº Å« ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ÀÏ¹Ý ´ëÁßÀÇ Àνİú À±¸®Àû ³íÀïÀº Áö¿ª¿¡ µû¶ó ±â¼ú ¼ö¿ëÀ» Á¦ÇÑÇÒ ¼ö ÀÖÀ¸¸ç, Åõ¸íÇÑ Ä¿¹Â´ÏÄÉÀ̼ǰú Áö¿ª»çȸ Âü¿© ³ë·ÂÀÌ ÇÊ¿äÇÕ´Ï´Ù. Çõ½ÅÀº º£À̽º ¿¡µðÅÍ¿Í °°Àº Â÷¼¼´ë ÆíÁý µµ±¸ÀÇ °³¹ß, Ä¡·á Àû¿ëÀ» À§ÇÑ Àü´Þ ¸ÞÄ¿´ÏÁòÀÇ °³¼±, Á¤Ã¥ ÀÔ¾ÈÀÚ¿ÍÀÇ Àû±ØÀûÀÎ ´ëÈ­¸¦ ÅëÇØ ±ÔÁ¦ º´¸ñÇö»óÀ» ÇØ°áÇÏ´Â µ¥ ÃÊÁ¡À» ¸ÂÃß¾î¾ß ÇÕ´Ï´Ù. À¯ÀüÀÚ ÆíÁý ½ÃÀåÀº ±Þ¼ÓÇÑ ±â¼ú ÁøÈ­¸¦ Ư¡À¸·Î Çϸç, À±¸®Àû, ±ÔÁ¦Àû »óȲÀ» Àß ÇìÃijª°©´Ï´Ù¸é ±â¾÷ÀÌ Çõ½ÅÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Â ºñ¿ÁÇÑ Åä¾çÀ» Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â À¯ÀüÀÚ ÆíÁý ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

À¯Àüü ÆíÁý ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ» ÅëÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤, Àü·«Àû ÀÇ»ç°áÁ¤, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ¿ÏÈ­Çϰí, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • Á¤ºÎ ÀÚ±Ý Áõ°¡¿Í À¯ÀüüÇÐ ÇÁ·ÎÁ§Æ® ¼ö Áõ°¡
    • À¯ÀüüÇÐÀÇ ÀÀ¿ë ºÐ¾ß È®´ë
    • °¨¿°º´°ú ¾ÏÀÇ ³ôÀº È®»ê
    • À¯ÀüÀÚ º¯Çü ÀÛ¹° »ý»ê·® Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ÈÆ·ÃÀ» ¹ÞÀº Àü¹®°¡ ºÎÁ·
    • À¯ÀüÀÚ Á¶»ç¿¡ ´ëÇÑ »çȸÀû Æò°¡ ÀúÇÏ
  • ½ÃÀå ±âȸ
    • Àü¹® ÀÇ·á ºÐ¾ß¿¡¼­ À¯ÀüÀÚ ÆíÁý »ç¿ë
    • CRISPR-Cas9 ½Ã½ºÅÛÀ» ÅëÇÑ À¯Àüü ÆíÁýÀÇ ¹ßÀü
  • ½ÃÀå °úÁ¦
    • À¯Àüü ºÐ¼® ÀåºñÀÇ °íºñ¿ë
    • ´ë·®ÀÇ ½ÃÄö½Ì µ¥ÀÌÅ͸¦ ¾ÈÀüÇÏ°Ô º¸°üÇÒ ¼ö ÀÖ½À´Ï´Ù.

Portre's Five Forces: À¯ÀüÀÚ ÆíÁý ½ÃÀå °ø·«À» À§ÇÑ Àü·« µµ±¸

Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : À¯ÀüÀÚ ÆíÁý ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ·Â ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº À¯ÀüÀÚ ÆíÁý ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® À¯Àüü ÆíÁý ½ÃÀå¿¡¼­°æÀï ±¸µµ ÆÄ¾Ç

À¯ÀüÀÚ ÆíÁý ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­, ÅëÇÕÀÇ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º À¯ÀüÀÚ ÆíÁý ½ÃÀå¿¡¼­ÀÇ º¥´õÀÇ ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â À¯ÀüÀÚ ÆíÁý ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÒ ¼ö ÀÖ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ À¯ÀüÀÚ ÆíÁý ½ÃÀå¿¡¼­ ¼º°øÇϱâ À§ÇÑ Àü·« ºÐ¼® ¹× Ãßõ

À¯ÀüÀÚ ÆíÁý ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö ÀÖµµ·Ï ÁغñÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • PorterÀÇ Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå À¯ÀüÀÚ ÆíÁý ½ÃÀå : ±â¼úº°

  • Antisense
  • CRISPR
  • Talen
  • Zinc Finger Nucleases

Á¦7Àå À¯ÀüÀÚ ÆíÁý ½ÃÀå : ¿ëµµº°

  • ¼¼Æ÷ÁÖ ¿£Áö´Ï¾î¸µ
  • À¯ÀüÀÚ °øÇÐ
    • µ¿¹° À¯ÀüÀÚ °øÇÐ
    • ½Ä¹° À¯ÀüÀÚ °øÇÐ

Á¦8Àå À¯ÀüÀÚ ÆíÁý ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • Çмú±â°ü ¹× Á¤ºÎ ¿¬±¸±â°ü
  • ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ¹× Á¦¾àȸ»ç
  • °è¾à¿¬±¸±â°ü

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ À¯ÀüÀÚ ÆíÁý ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ À¯ÀüÀÚ ÆíÁý ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ À¯ÀüÀÚ ÆíÁý ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023³â
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • Abcam PLC
  • AgriGenome Labs Pvt. Ltd.
  • Beam Therapeutics Inc.
  • Biocompare, Inc.
  • Danaher Corporation
  • Editas Medicine, Inc.
  • GenScript Biotech Corporation
  • Lonza Group AG
  • Merck KGaA
  • OriGene Technologies, Inc.
  • PerkinElmer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sangamo Therapeutics, Inc.
  • Thermo Fisher Scientific Inc.
  • Verve Therapeutics, Inc.
LSH

The Genome Editing Market was valued at USD 10.80 billion in 2023, expected to reach USD 16.54 billion in 2024, and is projected to grow at a CAGR of 53.22%, to USD 214.22 billion by 2030.

Genome editing, the scientific approach to modifying an organism's DNA, has gained significant traction in applications ranging from agriculture to health care. This technology is pivotal for its ability to create genetically modified organisms with specific desired traits, addressing issues such as disease resistance in crops and advancing therapeutic development in healthcare. The necessity of genome editing stems from its potential to solve pressing global issues, including food security and genetic disorders, by enabling precise and cost-effective genetic modifications. Its primary applications are in agriculture, for developing pest-resistant and higher-yield crops, and in healthcare, particularly in gene therapy to treat genetic conditions. Additionally, it's making strides in industrial biotechnology for biofuel production and environmental technology.

KEY MARKET STATISTICS
Base Year [2023] USD 10.80 billion
Estimated Year [2024] USD 16.54 billion
Forecast Year [2030] USD 214.22 billion
CAGR (%) 53.22%

Market growth in genome editing is primarily driven by increasing demand for advanced therapeutic solutions, continuous advancements in biotechnology, and a growing understanding of genetic diseases. The latest opportunities include expanding CRISPR applications in therapeutics and crop improvement programs to support sustainable and resilient food systems. Companies that invest in and partner with research institutions can leverage new patentable techniques in genome editing, gain regulatory approvals, and achieve early entry into emerging markets. Key recommendations for businesses would be to focus on developing gene editing tools with higher accuracy and fewer off-target effects, and the expansion of partnerships to enhance R&D capabilities.

However, the market faces significant challenges such as ethical concerns over genetic modifications, stringent regulatory environments, and potential socio-economic disparities impacting market adoption. Public perception and ethical debates could limit technology acceptance in some regions, necessitating transparent communication and community engagement initiatives. Innovation should focus on creating next-gen editing tools like base editors, improving delivery mechanisms for therapeutic applications, and addressing regulatory bottlenecks through proactive dialogue with policymakers. The genome editing market is characterized by rapid technological evolution, offering a fertile ground for businesses to innovate, provided they navigate ethical and regulatory landscapes adeptly.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Genome Editing Market

The Genome Editing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising government funding and growth in the number of genomics Projects
    • Growing application areas of genomics
    • High prevalence of infectious diseases and cancer
    • Increasing production of genetically modified crops
  • Market Restraints
    • Limited availability of trained professionals
    • Adverse public perception of genetic research
  • Market Opportunities
    • Use of genome editing in specialized medicine
    • Advancements in genome editing with CRISPR-Cas9 system
  • Market Challenges
    • High cost associated with genomics equipment
    • Secure storage of large volumes of sequenced data

Porter's Five Forces: A Strategic Tool for Navigating the Genome Editing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Genome Editing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Genome Editing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Genome Editing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Genome Editing Market

A detailed market share analysis in the Genome Editing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Genome Editing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Genome Editing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Genome Editing Market

A strategic analysis of the Genome Editing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Genome Editing Market, highlighting leading vendors and their innovative profiles. These include Abcam PLC, AgriGenome Labs Pvt. Ltd., Beam Therapeutics Inc., Biocompare, Inc., Danaher Corporation, Editas Medicine, Inc., GenScript Biotech Corporation, Lonza Group AG, Merck KGaA, OriGene Technologies, Inc., PerkinElmer Inc., Regeneron Pharmaceuticals, Inc., Sangamo Therapeutics, Inc., Thermo Fisher Scientific Inc., and Verve Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the Genome Editing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Technology, market is studied across Antisense, CRISPR, Talen, and Zinc Finger Nucleases.
  • Based on Application, market is studied across Cell Line Engineering and Genetic Engineering. The Genetic Engineering is further studied across Animal Genetic Engineering and Plant Genetic Engineering.
  • Based on End User, market is studied across Academic & Government Research Institutes, Biotechnology & Pharmaceutical Companies, and Contract Research Organizations.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising government funding and growth in the number of genomics Projects
      • 5.1.1.2. Growing application areas of genomics
      • 5.1.1.3. High prevalence of infectious diseases and cancer
      • 5.1.1.4. Increasing production of genetically modified crops
    • 5.1.2. Restraints
      • 5.1.2.1. Limited availability of trained professionals
      • 5.1.2.2. Adverse public perception of genetic research
    • 5.1.3. Opportunities
      • 5.1.3.1. Use of genome editing in specialized medicine
      • 5.1.3.2. Advancements in genome editing with CRISPR-Cas9 system
    • 5.1.4. Challenges
      • 5.1.4.1. High cost associated with genomics equipment
      • 5.1.4.2. Secure storage of large volumes of sequenced data
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Genome Editing Market, by Technology

  • 6.1. Introduction
  • 6.2. Antisense
  • 6.3. CRISPR
  • 6.4. Talen
  • 6.5. Zinc Finger Nucleases

7. Genome Editing Market, by Application

  • 7.1. Introduction
  • 7.2. Cell Line Engineering
  • 7.3. Genetic Engineering
    • 7.3.1. Animal Genetic Engineering
    • 7.3.2. Plant Genetic Engineering

8. Genome Editing Market, by End User

  • 8.1. Introduction
  • 8.2. Academic & Government Research Institutes
  • 8.3. Biotechnology & Pharmaceutical Companies
  • 8.4. Contract Research Organizations

9. Americas Genome Editing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Genome Editing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Genome Editing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abcam PLC
  • 2. AgriGenome Labs Pvt. Ltd.
  • 3. Beam Therapeutics Inc.
  • 4. Biocompare, Inc.
  • 5. Danaher Corporation
  • 6. Editas Medicine, Inc.
  • 7. GenScript Biotech Corporation
  • 8. Lonza Group AG
  • 9. Merck KGaA
  • 10. OriGene Technologies, Inc.
  • 11. PerkinElmer Inc.
  • 12. Regeneron Pharmaceuticals, Inc.
  • 13. Sangamo Therapeutics, Inc.
  • 14. Thermo Fisher Scientific Inc.
  • 15. Verve Therapeutics, Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦